Moleculin Biotech Inc (NASDAQ:MBRX) — Market Cap & Net Worth
Market Cap & Net Worth: Moleculin Biotech Inc (MBRX)
Moleculin Biotech Inc (NASDAQ:MBRX) has a market capitalization of $22.47 Million ($22.47 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24662 globally and #5045 in its home market, demonstrating a -1.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Moleculin Biotech Inc's stock price $2.51 by its total outstanding shares 49498576 (49.50 Million). Analyse Moleculin Biotech Inc (MBRX) cash flow conversion to see how efficiently the company converts income to cash.
Moleculin Biotech Inc Market Cap History: 2016 to 2026
Moleculin Biotech Inc's market capitalization history from 2016 to 2026. Data shows change from $10.16 Billion to $124.24 Million (-43.48% CAGR).
Index Memberships
Moleculin Biotech Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #716 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2355 of 3165 |
Weight: Moleculin Biotech Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Moleculin Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Moleculin Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
920673.51x
Moleculin Biotech Inc's market cap is 920673.51 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $8.29 Billion | $9.00K | -$9.80 Million | 920673.51x | N/A |
Competitor Companies of MBRX by Market Capitalization
Companies near Moleculin Biotech Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Moleculin Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Moleculin Biotech Inc Historical Marketcap From 2016 to 2026
Between 2016 and today, Moleculin Biotech Inc's market cap moved from $10.16 Billion to $ 124.24 Million, with a yearly change of -43.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $124.24 Million | -24.17% |
| 2025 | $163.84 Million | +94.71% |
| 2024 | $84.15 Million | -86.80% |
| 2023 | $637.34 Million | -19.02% |
| 2022 | $787.03 Million | -43.01% |
| 2021 | $1.38 Billion | -61.11% |
| 2020 | $3.55 Billion | -12.89% |
| 2019 | $4.08 Billion | -12.01% |
| 2018 | $4.63 Billion | -44.09% |
| 2017 | $8.29 Billion | -18.42% |
| 2016 | $10.16 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Moleculin Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.47 Million USD |
| MoneyControl | $22.47 Million USD |
| MarketWatch | $22.47 Million USD |
| marketcap.company | $22.47 Million USD |
| Reuters | $22.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Moleculin Biotech Inc
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 po… Read more